C970 Stock Chart & Stats
€5.16
€0.00(0.00%)
At close: 4:00 PM EDT
€5.16
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€8.33M
Enterprise Value€11.51M
Total Cash (Recent Filing)€3.65M
Total Debt (Recent Filing)€1.80M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 05, 2026EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.72
Shares Outstanding7,444,378
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.58Price Target Upside-30.60% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
Regulatory And Clinical ProgressThe completed clinical and analytical work, together with the dual FDA submission, advances the Flu A/B and RSV assay toward commercialization. Regulatory progress can strengthen the platform’s credibility, support broader customer adoption, and create a foundation for recurring diagnostic-kit revenue.
International Platform ExpansionInternational partnerships and localized production initiatives broaden Co-Diagnostics’ commercial reach beyond its existing base. If execution continues, regional manufacturing and distribution could improve market access, support decentralized testing deployments, and create more durable platform utilization.
Lower Operating Expense BaseThe reduction in operating expenses and narrower adjusted EBITDA loss indicate meaningful cost control while regulatory and product programs continue. A leaner cost structure can reduce the amount of revenue needed to approach break-even and preserve resources for commercialization priorities.
Bears Say
Severe Revenue DeteriorationThe collapse in revenue shows that prior demand has not translated into a sustained commercial base. With TTM sales still very small, the company has limited operating scale, weak absorption of fixed costs, and substantial execution risk in converting its pipeline into recurring revenue.
Persistent Cash BurnPersistent negative operating and free cash flow means current operations are consuming capital rather than funding growth internally. Continued burn reduces financial flexibility, increases dependence on external funding, and may constrain the company’s ability to sustain clinical and commercialization programs.
Tight Liquidity And Dilution RiskThe financing supplies near-term liquidity but places a senior claim on substantially all assets and requires rapid weekly repayment. Conversion features, discounts and commitment shares can also dilute existing holders, highlighting funding pressure and reducing flexibility in future capital allocation.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics Inc’s price range in the past 12 months?
Co-Diagnostics Inc lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics Inc’s market cap?
Co-Diagnostics Inc’s market cap is €8.33M.
When is Co-Diagnostics Inc’s upcoming earnings report date?
Co-Diagnostics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 22 days.
How were Co-Diagnostics Inc’s earnings last quarter?
Co-Diagnostics Inc released its earnings results on Aug 13, 2026. The company reported -€1.303 earnings per share for the quarter.
Is Co-Diagnostics Inc overvalued?
According to Wall Street analysts Co-Diagnostics Inc’s price is currently Overvalued.
Does Co-Diagnostics Inc pay dividends?
Co-Diagnostics Inc does not currently pay dividends.
What is Co-Diagnostics Inc’s EPS estimate?
Co-Diagnostics Inc’s EPS estimate is -1.12.
How many shares outstanding does Co-Diagnostics Inc have?
Co-Diagnostics Inc has 7,444,378 shares outstanding.
What happened to Co-Diagnostics Inc’s price movement after its last earnings report?
Co-Diagnostics Inc reported an EPS of -€1.303 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics Inc?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics Inc
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.View all DE:C970 earnings summariesC970 Stock 12 Month Forecast
Average Price Target
€3.58
▼(-30.60% Downside)
Technical Analysis
Sintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―